03697nas a2200661   4500000000100000008004100001653001100042653001100053653000900064653002400073653000900097653002200106653001600128653001700144653003000161653002000191653001700211653002600228653001500254653003000269653002600299653003200325653002400357653002800381653002800409653001800437653003300455653002600488653003100514653001300545653002200558653001500580100002200595700001900617700002200636700001800658700001500676700002400691700002100715700001900736700002200755700001600777700002200793700002200815700002000837700001800857700001600875700001800891700002100909700002200930700001500952700001600967245011000983300001001093490000701103520191101110022001403021       2018                            d10aFemale10aHumans10aAged10aDouble-Blind Method10aMale10aTreatment Outcome10aMiddle Aged10aRisk Factors10aPredictive Value of Tests10aRisk Assessment10aTime Factors10aKaplan-Meier Estimate10abiomarkers10aDiabetes Mellitus, Type 210aMultivariate Analysis10aProportional Hazards Models10aHypoglycemic Agents10aAcute Coronary Syndrome10aChi-Square Distribution10aBlood Glucose10aMyocardial Revascularization10aGlycated Hemoglobin A10aNatriuretic Peptide, Brain10aOxazoles10aPeptide Fragments10aThiophenes1 aGrobbee Diederick1 aToyama Tadashi1 aSavonitto Stefano1 aMorici Nuccia1 aNozza Anna1 aCosentino Francesco1 aFilardi Pasquale1 aMurena Ernesto1 aMorocutti Giorgio1 aFerri Marco1 aCavallini Claudio1 aEijkemans Marinus1 aStähli Barbara1 aSchrieks Ilse1 aHeerspink H1 aMalmberg Klas1 aSchwartz Gregory1 aA Lincoff Michael1 aRyden Lars1 aTardif Jean00aPredictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.  a14-230 v153 a<p><b>AIM: </b>To define the predictors of long-term mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome.</p><p><b>METHODS AND RESULTS: </b>A total of 7226 patients from a randomized trial, testing the effect on cardiovascular outcomes of the dual peroxisome proliferator-activated receptor agonist aleglitazar in patients with type 2 diabetes mellitus and recent acute coronary syndrome (AleCardio trial), were analysed. Median follow-up was 2 years. The independent mortality predictors were defined using Cox regression analysis. The predictive information provided by each variable was calculated as percent of total chi-square of the model. All-cause mortality was 4.0%, with cardiovascular death contributing for 73% of mortality. The mortality prediction model included N-terminal proB-type natriuretic peptide (adjusted hazard ratio = 1.68; 95% confidence interval = 1.51-1.88; 27% of prediction), lack of coronary revascularization (hazard ratio = 2.28; 95% confidence interval = 1.77-2.93; 18% of prediction), age (hazard ratio = 1.04; 95% confidence interval = 1.02-1.05; 15% of prediction), heart rate (hazard ratio = 1.02; 95% confidence interval = 1.01-1.03; 10% of prediction), glycated haemoglobin (hazard ratio = 1.11; 95% confidence interval = 1.03-1.19; 8% of prediction), haemoglobin (hazard ratio = 1.01; 95% confidence interval = 1.00-1.02; 8% of prediction), prior coronary artery bypass (hazard ratio = 1.61; 95% confidence interval = 1.11-2.32; 7% of prediction) and prior myocardial infarction (hazard ratio = 1.40; 95% confidence interval = 1.05-1.87; 6% of prediction).</p><p><b>CONCLUSION: </b>In patients with type 2 diabetes mellitus and recent acute coronary syndrome, mortality prediction is largely dominated by markers of cardiac, rather than metabolic, dysfunction.</p>  a1752-8984